The Nasdaq Composite has erased early gains as losses for shares of Microsoft Corp. and Nvidia Corp. accelerated, weighing on the broader index. Microsoft shares were down more than 6% earlier, while ...

Check Point Software Technologies (NASDAQ:CHKP) reported its Q4 2024 earnings, surpassing Wall Street expectations with an earnings per share (EPS) of $2.70, compared to the forecasted $2.65. The ...

Cantor Fitzgerald reiterated its Overweight rating and $160.00 price target on Teradyne (NASDAQ:TER), following the company's latest earnings report. Teradyne, known for its automated test equipment, ...

U.S. stocks opened higher on Thursday, with the Dow shrugging off its premarket losses as investors reacted to the latest batch of corporate earnings and U.S. economic reports. Investors digested the ...

China Liberal Education Holdings Limited (CLEU) stock has reached a new 52-week low, trading at $1.03. While the company maintains a strong liquidity position with a current ratio of 16.25 and more ...

ENGLEWOOD, Colo. - XTI Aerospace, Inc. (NASDAQ:XTIA), a micro-cap aerospace company with a market capitalization of $15.16 million engaged in the development of advanced aircraft designs, announced ...

U.S. stocks are mostly rising following a rush of profit reports from some of the country’s most influential companies. The S&P 500 was up 0.6% in early trading. The Dow Jones Industrial Average was ...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm neutral on OPT stock.

With stock valuations climbing steadily over the past two years and artificial intelligence (AI) budgets of the big tech firms climbing by the year, it's only prudent to wonder if a bubble is in the ...

U.S. stocks ended lower on Wednesday, but off their lows, after the Federal Reserve left interest rates unchanged in its first policy meeting of the year. All three major indexes ended in negative ...

WEXFORD, Pa. - Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP), known for its work in cell therapy for various diseases, has announced a significant rebranding to COEPTIS, signaling a strategic ...

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. Could this be a great buying ...